These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33234482)

  • 1. Two distinct TP53 mutations in HNSCC primary tumor: Only one circulates in the blood.
    Ganci F; Allegretti M; Manciocco V; Fiorentino F; Sanguineti G; Giacomini P; Pellini R; Spinella F; Blandino G
    Oral Oncol; 2021 Apr; 115():105096. PubMed ID: 33234482
    [No Abstract]   [Full Text] [Related]  

  • 2. Computational analysis of TP53 mutational landscape unveils key prognostic signatures and distinct pathobiological pathways in head and neck squamous cell cancer.
    Caponio VCA; Troiano G; Adipietro I; Zhurakivska K; Arena C; Mangieri D; Mascitti M; Cirillo N; Lo Muzio L
    Br J Cancer; 2020 Oct; 123(8):1302-1314. PubMed ID: 32684626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review.
    Pall AH; Jakobsen KK; Grønhøj C; von Buchwald C
    Acta Oncol; 2020 Jul; 59(7):845-850. PubMed ID: 32223478
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison between mutational profiles in tumour tissue DNA and circulating tumour DNA in head and neck squamous cell carcinoma - A systematic review.
    Huang X; Leo P; Jones L; Duijf PHG; Hartel G; Kenny L; Vasani S; Punyadeera C
    Mutat Res Rev Mutat Res; 2024; 793():108477. PubMed ID: 37977279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression levels of miR-34-family microRNAs are associated with TP53 mutation status in head and neck squamous cell carcinoma.
    Metheetrairut C; Chotigavanich C; Amornpichetkul K; Keskool P; Ongard S; Metheetrairut C
    Eur Arch Otorhinolaryngol; 2019 Feb; 276(2):521-533. PubMed ID: 30515607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
    van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
    BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
    Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
    Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer.
    Chari NS; Ivan C; Le X; Li J; Mijiti A; Patel AA; Osman AA; Peterson CB; Williams MD; Pickering CR; Caulin C; Myers JN; Calin GA; Lai SY
    J Natl Cancer Inst; 2020 Mar; 112(3):266-277. PubMed ID: 31124563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutated
    Kampel L; Feldstein S; Tsuriel S; Hannes V; Carmel Neiderman NN; Horowitz G; Warshavsky A; Leider-Trejo L; Hershkovitz D; Muhanna N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Letter to the Editor: Next-Generation sequencing (NGS) profiling of matched tumor and Circulating Tumor DNA (ctDNA) in Head and Neck Squamous Cell Carcinoma (HNSCC)".
    Meivelu Moovendhan
    Oral Oncol; 2024 Oct; 157():106940. PubMed ID: 39013229
    [No Abstract]   [Full Text] [Related]  

  • 13. TP53 mutations in head and neck cancer.
    Nathan CA; Khandelwal AR; Wolf GT; Rodrigo JP; Mäkitie AA; Saba NF; Forastiere AA; Bradford CR; Ferlito A
    Mol Carcinog; 2022 Apr; 61(4):385-391. PubMed ID: 35218075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma.
    Zilberg C; Lee MW; Yu B; Ashford B; Kraitsek S; Ranson M; Shannon K; Cowley M; Iyer NG; Palme CE; Ch'ng S; Low TH; O'Toole S; Clark JR; Gupta R
    Mod Pathol; 2018 Feb; 31(2):275-287. PubMed ID: 28984303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
    Burgener JM; Zou J; Zhao Z; Zheng Y; Shen SY; Huang SH; Keshavarzi S; Xu W; Liu FF; Liu G; Waldron JN; Weinreb I; Spreafico A; Siu LL; de Almeida JR; Goldstein DP; Hoffman MM; De Carvalho DD; Bratman SV
    Clin Cancer Res; 2021 Aug; 27(15):4230-4244. PubMed ID: 34158359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-risk TP53 mutations predict poor primary treatment response of patients with head and neck squamous cell carcinoma.
    Caponio VCA; Zhurakivska K; Mascitti M; Togni L; Spirito F; Cirillo N; Lo Muzio L; Troiano G
    Oral Dis; 2024 May; 30(4):2018-2026. PubMed ID: 37501500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.
    Sano D; Xie TX; Ow TJ; Zhao M; Pickering CR; Zhou G; Sandulache VC; Wheeler DA; Gibbs RA; Caulin C; Myers JN
    Clin Cancer Res; 2011 Nov; 17(21):6658-70. PubMed ID: 21903770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined human papillomavirus typing and TP53 mutation analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.
    Daher T; Tur MK; Brobeil A; Etschmann B; Witte B; Engenhart-Cabillic R; Krombach G; Blau W; Grimminger F; Seeger W; Klussmann JP; Bräuninger A; Gattenlöhner S
    Head Neck; 2018 Jun; 40(6):1109-1119. PubMed ID: 29522268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.
    Peltonen JK; Vähäkangas KH; Helppi HM; Bloigu R; Pääkkö P; Turpeenniemi-Hujanen T
    Head Neck Oncol; 2011 Apr; 3():20. PubMed ID: 21513535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells.
    Xie TX; Zhou G; Zhao M; Sano D; Jasser SA; Brennan RG; Myers JN
    Laryngoscope; 2013 Jun; 123(6):1416-23. PubMed ID: 23625637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.